Who
Michael G. Grey
Director
Company insider
Files Form 4 as: Executive Chairman, OnKure Therapeutics; Executive Chairman, Mirum Pharmaceuticals; Executive Chairman, Spruce Biosciences; Director, Horizon Therapeutics Public Ltd Co; Director, BioMarin Pharmaceutical; Director, Mirati Therapeutics; Director, Achillion Pharmaceuticals; Director, Idm Pharma.
In numbers
- Trades disclosed
- 299
- Buys
- 1
- Sells
- 25
- Bought
- $95K
- Sold
- $24.8M
- Companies
- 9
- Companies where not an officer
- 5
- First trade
- 7 Mar 2006
- Last trade
- 7 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,350 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,772 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,980 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,772 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,980 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,700 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,700 at $0.00 | filing |
| 19 Dec 2025filed 23 Dec 2025 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 19 Dec 2025filed 23 Dec 2025 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $147K50,000 at $2.94 | filing |
| 19 Dec 2025filed 23 Dec 2025 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.9M50,000 at $78.00 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —387 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —387 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,255 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,255 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,499 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,499 | filing |
| 11 Dec 2025filed 15 Dec 2025 | SPRB Spruce Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —133 | filing |
News
Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)MIRM · seekingalpha.com · 12 Oct 2026
0 headlines in the last 90 days name Michael G. Grey; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.